Comparative Pharmacology
Head-to-head clinical analysis: BELEODAQ versus ISTODAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BELEODAQ versus ISTODAX.
BELEODAQ vs ISTODAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Belinostat is a histone deacetylase (HDAC) inhibitor that inhibits the enzymatic activity of HDACs, leading to accumulation of acetylated histones and non-histone proteins, resulting in cell cycle arrest and apoptosis in cancer cells.
Histone deacetylase (HDAC) inhibitor; induces cell cycle arrest and apoptosis in malignant cells.
1000 mg/m2 intravenously over 30 minutes on days 1-5 of a 21-day cycle.
14 mg/m2 intravenously over 4 hours on days 1, 8, and 15 of a 28-day cycle.
None Documented
None Documented
Terminal elimination half-life approximately 13 hours (range 10-18 hours) based on population pharmacokinetic analysis; supports once-daily dosing.
Terminal elimination half-life is approximately 3.0 hours (range 1.3–5.0 h) in patients with advanced malignancies; no clinically relevant accumulation with weekly dosing.
Primarily hepatic metabolism with subsequent biliary excretion; less than 10% of the dose recovered unchanged in urine.
Renal: <20% unchanged drug; fecal: ~70% (as metabolites); hepatic metabolism primarily via CYP3A4, with minor contributions from CYP2A6, CYP2C19, and CYP2E1.
Category C
Category C
HDAC Inhibitor
HDAC Inhibitor